Teva Pharmaceutical Industries Limited

Analysis of TEVA Stock

Technical Analysis TEVA has exhibited exceptional momentum, climbing nearly 40% in three months and significantly outperforming the market. While trading near its 52-week high suggests the stock may be extended, its shallow drawdowns indicate the uptrend has been relatively stable. The low beta further confirms this appreciation has occurred with below-market volatility.

Fundamental Analysis Revenue growth from Q3 to Q4 is positive, but profitability is inconsistent, with operating income declining despite higher sales. The company carries substantial debt, and key efficiency metrics like return on equity and asset turnover remain weak, pointing to operational challenges. Although liquidity is adequate, cash flow generation relative to debt is limited.

Valuation & Peer Comparison TEVA’s trailing P/E appears high, though the forward P/E of 18.6 suggests optimism about future earnings. However, an extremely elevated EV/EBITDA and a PEG ratio above 1.0 imply the stock may be overvalued relative to sector peers, which typically trade at lower multiples.

Risk Assessment With a beta of 0.72, TEVA is less volatile than the market, yet its maximum drawdown of –23% shows it can still experience sharp declines. Broader pharmaceutical risks such as regulatory changes or patent expirations remain relevant, though neutral short interest reflects modest speculative pressure.

---

Investment Recommendation

Consider a Buy with Caution

TEVA demonstrates strong price momentum and improving revenue, supported by a reasonable forward P/E. However, high debt, inconsistent profitability, and rich valuation multiples warrant caution. Investors should monitor earnings sustainability and debt management closely. This stock may suit those comfortable with pharmaceutical sector risks and optimistic about TEVA’s execution.

*Note: This is not investment advice, for reference only.*

RockFlow Model Forecast: Three Scenarios for 2026

Based on the provided analysis, here is a 12-month outlook for TEVA:

12-Month Outlook for TEVA

The primary positive catalyst for TEVA will be its ability to execute on its forward earnings expectations, justifying its current forward P/E ratio, and potentially leveraging its recent strong revenue momentum into more consistent profitability. Key risks center on its persistently high debt load, which could strain cash flow and limit strategic flexibility, alongside the threat that its elevated valuation multiples (EV/EBITDA, PEG) may contract if operational improvements disappoint. Given the absence of an analyst target, a prudent target price range is difficult to establish; the stock's performance will likely hinge on its next few earnings reports, with a break above the current 52-week high requiring clear evidence of sustained profit growth and disciplined debt management.

Wall Street Consensus

Most Wall Street analysts are optimistic about Teva Pharmaceutical Industries Limited's 12-month outlook, with consensus target around $33.86, indicating expected upside potential.

Overall, TEVA has investment potential but also faces challenges. Here are key factors to weigh before investing.

TEVA has demonstrated exceptionally strong performance over the past year, significantly outperforming the broader market. The stock's substantial gains highlight a powerful uptrend, though its lower beta suggests this appreciation has occurred with less volatility than the market average.

Over the short term, TEVA has shown remarkable strength, surging nearly 40% over three months while strongly outperforming the market by 35.77%. The positive one-month change indicates the bullish momentum has continued more recently, solidifying its impressive run.

Currently trading at $33.86, TEVA sits much closer to its 52-week high of $37.35 than its low of $12.47, placing it in the upper quadrant of its yearly range. While the dramatic ascent suggests the stock is extended, its relatively shallow maximum drawdown of -23.28% over the past year indicates the uptrend has been sustained without severe corrections.

Revenue & Profitability TEVA demonstrated sequential revenue growth from Q3 to Q4 2025, increasing from $4.48 billion to $4.71 billion. However, profitability metrics showed volatility with operating income declining significantly in Q4 despite higher revenue, indicating potential margin pressures from increased operating expenses. The net profit margin improved to 10.2% in Q4, though this appears heavily influenced by an unusual tax benefit rather than operational improvements.

Financial Health The company maintains a moderate debt ratio of 42.7% but carries substantial leverage with a debt-to-equity ratio of 2.2. While the interest coverage ratio of 5.8 suggests adequate earnings to service debt, the cash flow to debt ratio of just 0.09 indicates limited free cash flow generation relative to total debt obligations. Current and quick ratios above 1.0 and 0.8 respectively demonstrate reasonable short-term liquidity, though cash ratios remain modest.

Operational Efficiency TEVA's operational efficiency appears challenged with a return on equity of 6.2% and return on assets of just 1.2%, reflecting suboptimal capital allocation. Asset turnover of 0.12 suggests inefficient utilization of the company's asset base to generate revenue. The cash conversion cycle of 97 days, while improved from previous periods, still indicates room for improvement in working capital management.

Valuation Level: TEVA's trailing PE of 27.74 is elevated for a mature pharmaceutical company, though its more reasonable forward PE of 18.57 suggests anticipated earnings growth may improve the valuation picture. However, the extremely high EV/EBITDA of 87.85 and a PEG ratio above 1.0 signal significant valuation concerns, indicating the market is pricing in optimistic future performance that may not materialize.

Peer Comparison: Without specific industry average data, a precise peer comparison is not possible. Generally, a forward PE near 18.5 would be considered high relative to the broader pharmaceutical sector, which often trades at lower multiples. The combination of a high price-to-book ratio and EV/EBITDA further suggests TEVA is likely trading at a premium to its pharmaceutical industry peers.

Volatility risk for TEVA is moderate, as evidenced by a Beta of 0.72, indicating the stock is generally less volatile than the broader market. However, the one-year maximum drawdown of -23.28% highlights its potential for significant downside moves during market stress, suggesting that while its day-to-day swings may be dampened, it is not immune to substantial declines.

Other risks appear limited, with no reported short interest pointing to a broadly neutral to positive sentiment among institutional investors regarding the company's near-term prospects. Liquidity is typically robust for a stock of this size, reducing transaction cost risks, though standard sector-specific challenges like patent cliffs or regulatory pressures inherent to the pharmaceutical industry remain applicable.